PMID- 37169563
OWN - NLM
STAT- MEDLINE
DCOM- 20230515
LR  - 20230623
IS  - 1578-1267 (Electronic)
IS  - 0301-0546 (Linking)
VI  - 51
IP  - 3
DP  - 2023
TI  - Evolution of laboratory parameters in patients with lipid transfer protein 
      syndrome after 3 years of immunotherapy.
PG  - 80-84
LID - 10.15586/aei.v51i3.790 [doi]
AB  - Lipid transfer protein (LTP) syndrome is an increasingly prevailing disease, 
      especially in the young population, with severely affected quality of life. Since 
      2013, a specific treatment, called sublingual immunotherapy (SLIT), with peach 
      extract (SLIT-peach((R))) has been used, but with no long-term effectiveness 
      studies. The main objective of the present study was to assess the long-term 
      effectiveness of SLIT-peach((R)) and to relate the clinical evolution of patients. 
      This was an ambispective study conducted for 3 years. A total of 25 patients with 
      LTP syndrome were selected and treated with SLIT-peach((R)). They underwent a 
      provocation test in the first year with reintroduced foods that had produced 
      symptoms in the past. Analytical determination of specific immunoglobulin E (IgE) 
      and immunoglobulin G4 (IgG4) to peach (Pru p 3) was performed at the beginning of 
      treatment, at the first year of initiation, and at the end of treatment. These 
      data were compared with the control group comprising 14 patients with LTP 
      syndrome without treatment. A statistically significant decrease in specific IgE 
      to Pru p 3 at the end of the treatment and an increase in specific IgG4 to Pru p 
      3 1 year after treatment initiation were observed in the active group in relation 
      to tolerance to foods with LTPs. These results indicate that food tolerance 
      begins after the first year and is maintained after the end of 3 years of 
      treatment. In conclusion, treatment with SLIT-peach((R)) for 3 years is effective 
      for patients with LTP syndrome, preventing the evolution of the disease, allowing 
      patients to restart a diet with plant foods, and improving their quality of life.
FAU - Gonzalez Perez, Alejandra
AU  - Gonzalez Perez A
AD  - Allergology Section, General Hospital, Reina Sofia University, Murcia, Spain.
FAU - Escudero Pastor, Ana Isabel
AU  - Escudero Pastor AI
AD  - Allergology Section, General Hospital, Reina Sofia University, Murcia, Spain.
FAU - Sola Martinez, Rosa Alba
AU  - Sola Martinez RA
AD  - Departamento de Bioquimica y Biologia Molecular B e Inmunologia, Universidad de 
      Murcia.
FAU - Carbonell Martinez, Antonio
AU  - Carbonell Martinez A
AD  - Allergology Section, General Hospital, Reina Sofia University, Murcia, Spain; 
      med018934@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20230501
PL  - Singapore
TA  - Allergol Immunopathol (Madr)
JT  - Allergologia et immunopathologia
JID - 0370073
RN  - 0 (Plant Proteins)
RN  - 0 (Antigens, Plant)
RN  - 0 (lipid transfer protein)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 0 (Allergens)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - Humans
MH  - Plant Proteins
MH  - Antigens, Plant
MH  - Quality of Life
MH  - *Food Hypersensitivity/therapy/diagnosis
MH  - *Prunus persica
MH  - Immunoglobulin E
MH  - Allergens/therapeutic use
MH  - *Sublingual Immunotherapy
MH  - Immunoglobulin G
MH  - Syndrome
OTO - NOTNLM
OT  - LTP syndrome
OT  - Pru p 3
OT  - allergic reaction
OT  - anaphylaxis
OT  - food tolerance
OT  - immune tolerance
OT  - immunotherapy
OT  - lipid transfer proteins
EDAT- 2023/05/12 01:07
MHDA- 2023/05/15 06:41
CRDT- 2023/05/11 21:23
PHST- 2022/11/02 00:00 [received]
PHST- 2023/01/16 00:00 [accepted]
PHST- 2023/05/15 06:41 [medline]
PHST- 2023/05/12 01:07 [pubmed]
PHST- 2023/05/11 21:23 [entrez]
AID - 10.15586/aei.v51i3.790 [doi]
PST - epublish
SO  - Allergol Immunopathol (Madr). 2023 May 1;51(3):80-84. doi: 
      10.15586/aei.v51i3.790. eCollection 2023.